MRTX:NSD-Mirati Ther (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 49.59

Change

-21.93 (-30.66)%

Market Cap

USD 5.54B

Volume

7.18M

Avg Analyst Target

USD 99.45 (+100.55%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

MRTX Stock Forecast & Price:
Based on the Mirati Ther stock forecasts from 9 analysts, the average analyst target price for Mirati Ther is USD 99.45 over the next 12 months. Mirati Ther’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Mirati Ther is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Mirati Ther’s stock price was USD 49.59. Mirati Ther’s stock price has changed by -45.73% over the past week, -17.24% over the past month and -63.93% over the last year.

About Mirati Ther (MRTX:NSD)

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non- ...Read More

Company Website : https://www.mirati.com

Address : 3545 Cray Court, San Diego, CA, United States, 92121

Employees : 413

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.83

52 Week High : 154.17

Short Ratio : 9.79

52 Week Low : 32.96

Shorted Shares : 8,084,646

200 Day Moving Average : 72.01

Shorted Shares Previous Month : 7,727,636

50 Day Moving Average : 72.40

Shares Held By Insiders : 1.03%

Short Percentage : 17.37%

Shares Held by Institutions : 112.23%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+16.80 (+2.25%)

 USD83.46B 192.56 12.35
VRTX Vertex Pharmaceuticals Inc

+5.77 (+1.85%)

 USD82.49B 25.21 17.39
MRNA Moderna Inc

+5.46 (+3.15%)

 USD67.59B 6.10 4.60
BNTX BioNTech SE

+1.01 (+0.62%)

 USD41.19B 3.97 1.87
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
GMAB Genmab AS

+0.43 (+0.95%)

 USD31.54B 37.65 3.71
ALNY Alnylam Pharmaceuticals Inc

+11.69 (+5.32%)

 USD27.02B N/A -29.83
SGEN Seagen Inc

+1.45 (+1.23%)

 USD22.73B 55.02 -38.32
BGNE BeiGene Ltd

+5.80 (+3.09%)

 USD21.81B N/A -8.80
ARGX argenx NV ADR

-1.17 (-0.30%)

 USD21.32B N/A -22.20

ETFs Containing MRTX

Symbol Name Weight Mer Price(Change) Market Cap
DWAQ Invesco DWA NASDAQ Moment.. 0.00 % 0.60 %

N/A

 USD0.05B
PDP Invesco DWA Momentum ETF 0.00 % 0.62 %

-0.18 (-0.25%)

 USD1.11B
IS0R:F iShares II Public Limited.. 0.00 % 0.55 %

-0.32 (-0.38%)

 USD3.29B
IS0R:XETRA iShares High Yield Corpor.. 0.00 % 0.55 %

+0.17 (+0.20%)

 USD2.71B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -66.19% 38% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.19% 38% F 24% F
Trailing 12 Months  
Capital Gain -65.10% 46% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.10% 46% F 26% F
Trailing 5 Years  
Capital Gain 207.06% 90% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 207.06% 90% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 45.63% 89% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.63% 89% B+ 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 75.63% 24% F 15% F
Risk Adjusted Return 60.34% 97% A+ 91% A-
Market Capitalization 5.54B 97% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.91 21% F 18% F
Price / Cash Flow Ratio -14.26 84% B 74% C
EV/EBITDA -5.92 83% B 77% C+
Management Effectiveness  
Return on Equity -66.70% 46% F 24% F
Return on Invested Capital -41.81% 60% D- 27% F
Return on Assets -36.42% 34% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.79 18% F 10% F
Short Percent 17.37% 7% F 8% F
Beta 0.83 66% D 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector